Cargando…
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment fail...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344729/ https://www.ncbi.nlm.nih.gov/pubmed/37457134 http://dx.doi.org/10.20517/cdr.2023.16 |
_version_ | 1785072923459977216 |
---|---|
author | Sun, Xiangyu Zhao, Ping Lin, Jierou Chen, Kun Shen, Jianliang |
author_facet | Sun, Xiangyu Zhao, Ping Lin, Jierou Chen, Kun Shen, Jianliang |
author_sort | Sun, Xiangyu |
collection | PubMed |
description | Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment failure. Chemotherapy resistance refers to the resistance of tumor cells and/or tissues to a drug, usually inherent or developed during treatment. Therefore, an urgent need to research the ideal drug delivery system to overcome the shortcoming of traditional chemotherapy. The rapid development of nanotechnology has brought us new enlightenments to solve this problem. The novel nanocarrier provides a considerably effective treatment to overcome the limitations of chemotherapy or other drugs resulting from systemic side effects such as resistance, high toxicity, lack of targeting, and off-target. Herein, we introduce several tumor MDR mechanisms and discuss novel nanoparticle technology applied to surmount cancer drug resistance. Nanomaterials contain liposomes, polymer conjugates, micelles, dendrimers, carbon-based, metal nanoparticles, and nucleotides which can be used to deliver chemotherapeutic drugs, photosensitizers, and small interfering RNA (siRNA). This review aims to elucidate the advantages of nanomedicine in overcoming cancer drug resistance and discuss the latest developments. |
format | Online Article Text |
id | pubmed-10344729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | OAE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103447292023-07-15 Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system Sun, Xiangyu Zhao, Ping Lin, Jierou Chen, Kun Shen, Jianliang Cancer Drug Resist Review Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment failure. Chemotherapy resistance refers to the resistance of tumor cells and/or tissues to a drug, usually inherent or developed during treatment. Therefore, an urgent need to research the ideal drug delivery system to overcome the shortcoming of traditional chemotherapy. The rapid development of nanotechnology has brought us new enlightenments to solve this problem. The novel nanocarrier provides a considerably effective treatment to overcome the limitations of chemotherapy or other drugs resulting from systemic side effects such as resistance, high toxicity, lack of targeting, and off-target. Herein, we introduce several tumor MDR mechanisms and discuss novel nanoparticle technology applied to surmount cancer drug resistance. Nanomaterials contain liposomes, polymer conjugates, micelles, dendrimers, carbon-based, metal nanoparticles, and nucleotides which can be used to deliver chemotherapeutic drugs, photosensitizers, and small interfering RNA (siRNA). This review aims to elucidate the advantages of nanomedicine in overcoming cancer drug resistance and discuss the latest developments. OAE Publishing Inc. 2023-06-20 /pmc/articles/PMC10344729/ /pubmed/37457134 http://dx.doi.org/10.20517/cdr.2023.16 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Sun, Xiangyu Zhao, Ping Lin, Jierou Chen, Kun Shen, Jianliang Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system |
title | Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system |
title_full | Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system |
title_fullStr | Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system |
title_full_unstemmed | Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system |
title_short | Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system |
title_sort | recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344729/ https://www.ncbi.nlm.nih.gov/pubmed/37457134 http://dx.doi.org/10.20517/cdr.2023.16 |
work_keys_str_mv | AT sunxiangyu recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem AT zhaoping recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem AT linjierou recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem AT chenkun recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem AT shenjianliang recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem |